Becton, Dickinson and Company (NYSE:BDX) Updates FY24 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY24 earnings guidance on Thursday. The company provided earnings per share guidance of $12.95-13.15 for the period, compared to the consensus earnings per share estimate of $12.95. The company issued revenue guidance of ~$20.1-20.3 billion, compared to the consensus revenue estimate of $20.30 billion.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BDX. Barclays upped their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an overweight rating in a research note on Monday, February 5th. Raymond James increased their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an outperform rating in a research note on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average target price of $280.00.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock traded up $6.41 during trading hours on Thursday, hitting $240.13. 910,753 shares of the company traded hands, compared to its average volume of 1,372,935. The firm has a market cap of $69.37 billion, a P/E ratio of 55.41, a P/E/G ratio of 1.94 and a beta of 0.45. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. The firm’s 50-day simple moving average is $238.75 and its two-hundred day simple moving average is $240.71. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating the consensus estimate of $2.97 by $0.20. The firm had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. Becton, Dickinson and Company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the company earned $2.86 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.58%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 90.05%.

Insider Activity

In related news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.